2619 Fluoroacetamide Fluoroacetamide is an organic compound based on acetamide with one fluorine atom replacing hydrogen on the methyl group. it is a metabolic poison which disruptes the citric acid cycle and is used as a rodenticide (L1161). 640-19-7 12542 C2H4FNO 77.027690 Colorless crystalline powder (A639). 108°C 1000 mg/mL at 25°C [SHIU,WY et al. (1990)] Inhalation (L1160) ; oral (L1160) ; dermal (L1160) ; eye contact (L1160). Fluoroacetate produces its toxin action by inhibiting the citric acid cycle. The fluorine substituted acetate becomes incorporated, as a normal acetate, into fluoroacetyl coenzyme A, which condenses with oxaloacetate to form fluorocitrate. Fluorocitrate inhibits the enzyme aconitase and thereby inhibits the conversion of citrate to isocitrate. As a result there is an accumulation of large quantities of citrate in the tissue, and the cycle is blocked. The heart and CNS are the most critical tissues involved in poisoning by general inhibition of oxydative energy metabolism (A640). Fluoroacetamide is metabolized by the fluoroacetate specific dehalogenase (A323). LD50: 4-15 mg/kg (Oral, Rat) (A640) LD50: 80 mg/kg (Dermal, Rat) (T14) No indication of carcinogenicity to humans (not listed by IARC). Used as rodenticide, insecticide proposed mainly for use on fruits to combat scale insects, aphids, mites (T50). Metabolic acidosis, hyperglycemia, hyperuricemia, elevated serum levels of hepatic transaminases, and elevated serum creatinine levels may occur. Tachycardia, ventricular tachycardia or fibrillation, and sudden onset of asystole may occur (T36). Nausea, vomiting, excessive salivation, abdominal pain, numbness, a tingling sensation, and apprehension are seen initially, and may last for up to 6 hours. Numbness and tingling of the face, excessive salivation, blurred vision, peripheral paresthesias, convulsions, and coma followed inhalation and dermal contact with fluoroacetate (T36). Consider gastric lavage after ingestion, and/or administer charcoal as a slurry. In case of refractory seizures after following ingestion, consider continuous infusion of midazolam, propofol, and/or pentobarbital. Hyperthermia, lactic acidosis and muscle destruction may necessitate use of neuromuscular blocking agents with continuous EEG monitoring. If the exposure occurred through inhalation, move patient to fresh air. Monitor for respiratory distress. If cough or difficulty breathing develops, evaluate for respiratory tract irritation, bronchitis, or pneumonitis. Administer oxygen and assist ventilation as required. Treat bronchospasm with inhaled beta2 agonist and oral or parenteral corticosteroids. In case of acute lung injury, maintain ventilation and oxygenation and evaluate with frequent arterial blood gas or pulse oximetry monitoring. Following eye exposure, irrigate exposed eyes with copious amounts of room temperature water for at least 15 minutes. In case of dermal exposure, Remove contaminated clothing and wash exposed area thoroughly with soap and water. (T36) 2009-07-05T03:38:39Z 2026-03-27T00:42:12Z Glutathione S-transferase Mu 2 (P28161) (A323). C18675 53124 C007741 Fluoroacetamide true Glutathione S-transferase Mu 2 (P28161) (A323) NC(=O)CF C2H4FNO InChI=1S/C2H4FNO/c3-1-2(4)5/h1H2,(H2,4,5) FVTWJXMFYOXOKK-UHFFFAOYSA-N 77.0577 77.02769196 Exogenous Solid CHEMBL160811 12025 CHEM002102 DTXSID2034255 2-fluoroacetamide